key: cord-0852014-fz2hos6j
authors: Leroux, Xavier; Schock, Maud; Augereau, Olivier; Lessire, Henry; Bouterra, Charles; Belilita, Lounis; Rerat, Pierre; Alvarez, Antonio; Martinot, Martin; Gerber, Victor
title: Factors associated with mechanical ventilation in SARS‐CoV‐2 patients treated with high‐flow nasal cannula oxygen and outcomes
date: 2021-11-17
journal: J Med Virol
DOI: 10.1002/jmv.27442
sha: b1be5124c8c7dcd20419d9ae2298fb00733b5bf0
doc_id: 852014
cord_uid: fz2hos6j

Five percent of patients infected with SARS‐CoV‐2 require advanced respiratory support. The high‐flow nasal cannula oxygenotherapy (HFNCO) appears to be effective and safe to reduce the need for mechanical ventilation. However, the factors associated with HFNCO failure as well as the outcomes of patients receiving this noninvasive respiratory strategy remain unclear. Thus, we performed this study to determine factors leading to intubation of SARS‐CoV‐2 patients treated with HFNCO and patients’ outcomes. We retrospectively analyzed the medical charts of patients admitted in our ICU center for acute respiratory failure due to SARS‐CoV‐2 infection and who initially benefited from HFNCO, between September 1, 2020, and March 1, 2021. We included all adults patients who received HFNCO and compared two groups: those treated with HFNCO alone and those who failed HFNCO. Patients treated with HFNCO and secondarily limited to the use of mechanical ventilation were excluded from the analysis. Sixty‐nine patients were included, 33 were treated with HFNCO alone and 36 failed HFNCO. We found more patients with shock in the HFNCO failure group (p = 0.001). The mean IGSII score was higher in the HFNCO failure group (p < 0.001). The minimum PaO(2)/FiO(2) was lower in the HFNCO failure group (p = 0.024). The length of stay in ICU was higher in the HFNCO failure group (p < 0.001). The mean duration of HFNCO before intubation was 1.77 days. Six‐week mortality was higher in the HFNCO failure group (p = 0.034). Ten patients had a complication during intubation. The HFNCO leads to reduce the intubation rate, the length of stay in ICU, and the mortality. Determining the factors associated with HFNCO failure is important to avoid complications following late intubation.

We retrospectively analyzed the medical charts of patients admitted in our ICU center for acute respiratory failure due to SARS-CoV-2 infection and who initially benefited from HFNCO, between September 1, 2020, and March 1, 2021. Laboratory confirmation of SARS-CoV-2 was defined as a positive result of a nucleic acid amplification test of nasopharyngeal swabs. We included all adults patients who received HFNCO for at least 2 h and compared two groups: those treated with HFNCO alone and those who failed HFNCO. HFNCO failure was defined as the subsequent need for invasive mechanical ventilation. Patients treated with HFNCO and secondarily limited to the use of mechanical ventilation were excluded from the analysis. Intubation criteria were left at the discretion of physicians and most often consisted, over the duration of the study, in the persistence of hypoxemia associated with respiratory distress signs despite the use of HFNCO with FiO 2 greater than 80%.

For each patient we collected demographic data, underlying diseases, clinical characteristics at admission, IGSII score, clinical course, and patients' outcomes. The groups were compared using a Student's t test and a Fischer's exact test for quantitative and qualitative variables, respectively. The study was approved by the Ethical Commit- 

Sixty-nine patients were included, 33 were treated with HFNCO alone and 36 failed HFNCO. Three patients were treated with HFNCO and secondarily limited to the use of mechanical ventilation.

These three patients were highly comorbid. The first patient was 59 years old and had a stage four emphysematous chronic obstructive pulmonary disease (COPD); the second was 76 years old and had high blood pressure, diabetes mellitus, Stage 4 renal disease, and ischemic heart disease; the last patient was 77 years old and had high blood pressure, diabetes mellitus, morbid obesity (body mass index [BMI] at 40), cirrhosis, and loss of autonomy. Patients' characteristics are presented in Table 1 

The use of HFNCO avoided the need for intubation in 47.8% of the cases in our study. Several studies, mostly with smaller cohorts, found a decreased intubation rate of patients treated with HFNCO. However, the HFNCO failure rate ranges from 32% to 71.6%. 7, 8, [10] [11] [12] The differences in HFNCO failure could be explained by more frequent use of the prone position which improves SpO 2 , PaO 2 , and lower PCO 2 , or noninvasive ventilation in combination with HFNO, which can be used in salvage therapy. 11, 13 Indeed, in our study, the use of noninvasive ventilation in 27 patients allowed to avoid mechanical ventilation in 33.3% of cases.

In line with other studies, we found that patients with shock were significantly more intubated. 5, 8, 12 We also found a lower minimal PaO 2 /FiO 2 in the HFNCO failure group. This association was described by other studies with fewer patients. 8, 10 Rather than following the PaO 2 /FiO 2 , the use of the ROX index, the ratio of pulse oximetry (SpO 2 )/FiO 2 to the respiratory rate, which was initially developed to predict HFNCO failure in hypoxemic patients, seems interesting. 14 Several studies evaluated the ROX index in SARS-CoV-2 infected patients with acute respiratory failure and treated with HFNCO. They found an association between a high ROX score within 24 h of HFNCO initiation and intubation rate. 8, 11 However, Blez et al.

single-center and the prospective study suggested that the monitoring of the respiratory rate is efficacious to predict the HFNCO failure, in particular in the first hour and that the monitoring of other respiratory parameters like the ROX score did not provide any value in addition to the respiratory rate. 15 The presence of shock and the respiratory rate is among the five variables, together with the Glasgow coma scale, the number of comorbidities, and the age, present in the nomogram proposed by Liu et al. to predict the failure of noninvasive respiratory strategy. 12 We found a higher IGSII score in the HFNCO failure group and we noticed that the HFNCO mean duration before failure was 1.77 days. Other studies also found that HFNCO failure occurs early and usually within 48 h. 8, 11 The IGSII score assessing the severity within the first 24 h of patients admitted in ICU appears to be an interesting predicting factor for HFNCO failure.

We found that patients successfully treated with HFNCO had a shorter length of stay in ICU. However, the impact of HFNCO on the length of stay in ICU diverges in the literature. 6, 8, 11 These differences could be explained by a higher frequency of patients presenting less severe infection or by the achievement of early therapeutic limitation in patients treated with HFNCO in our cohort. However, the patients in the HFNCO alone group still presented an average PaO 2 /FiO 2 

Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study

A rationale for use of high flow nasal cannula for select patients with suspected or confirmed severe acute respiratory syndrome coronavirus-2 infection

High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission

No evidence of increasing COVID-19 in health care workers after implementation of high flow nasal cannula: a safety evaluation

High-flow nasal cannula in critically ill patients with severe COVID-19

Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia

Timing of intubation and mortality among critically ill coronavirus disease 2019 patients: a single-center cohort study

Predictive factors associated with high-flow nasal cannula success for COVID-19-related acute hypoxemic respiratory failure

Failure of high-flow nasal cannula therapy may delay intubation and increase mortality

High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection

High-flow nasal cannula for COVID-19 patients: a multicenter retrospective study in China

A simple nomogram for predicting failure of non-invasive respiratory strategies in adults with COVID-19: a retrospective multicentre study

Prone positioning in high-flow nasal cannula for COVID-19 patients with severe hypoxemia: a pilot study

Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index

Monitoring of highflow nasal cannula for SARS-CoV-2 severe pneumonia: less is more, better look at respiratory rate

Complications of endotracheal intubation in the critically ill

Incidence of and risk factors for severe cardiovascular collapse after endotracheal intubation in the ICU: a multicenter observational study

Cardiac arrest and mortality related to intubation procedure in critically ill adult patients: a multicenter cohort study

Timing of invasive mechanical ventilation and mortality among patients with severe COVID-19-associated acute respiratory distress syndrome

Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and metaanalysis of non-randomized cohort studies